Missed GME or NVDA? Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PRCT Stock Forecast 2025-2026
$56.97
Current Price
$3.17B
Market Cap
Buy 8
Hold 2
Sell 0
Wall St Analyst Ratings
Distance to PRCT Price Targets
+58.0%
To High Target of $90.00
+36.0%
To Median Target of $77.50
+5.3%
To Low Target of $60.00
PRCT Price Momentum
+0.7%
1 Week Change
-9.4%
1 Month Change
-11.3%
1 Year Change
-29.2%
Year-to-Date Change
-45.1%
From 52W High of $103.81
+21.1%
From 52W Low of $47.04
📊 TOP ANALYST CALLS
Did PRCT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if PROCEPT is one of their latest high-conviction picks.
Latest PRCT Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, PRCT has a bullish consensus with a median price target of $77.50 (ranging from $60.00 to $90.00). The overall analyst rating is Strong Buy (8.8/10). Currently trading at $56.97, the median forecast implies a 36.0% upside. This outlook is supported by 8 Buy, 2 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Richard Newitter at Truist Securities, projecting a 58.0% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PRCT Analyst Ratings
8
Buy
2
Hold
0
Sell
PRCT Price Target Range
Low
$60.00
Average
$77.50
High
$90.00
Current: $56.97
Latest PRCT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PRCT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 7, 2025 | Oppenheimer | Suraj Kalia | Perform | Initiates | $0.00 |
| Apr 25, 2025 | B of A Securities | Craig Bijou | Buy | Maintains | $84.00 |
| Apr 11, 2025 | Truist Securities | Richard Newitter | Buy | Maintains | $70.00 |
| Feb 26, 2025 | Morgan Stanley | Patrick Wood | Overweight | Maintains | $95.00 |
| Feb 26, 2025 | Truist Securities | Richard Newitter | Buy | Reiterates | $90.00 |
| Dec 3, 2024 | Wells Fargo | Nathan Treybeck | Overweight | Reinstates | $112.00 |
| Dec 2, 2024 | Morgan Stanley | Patrick Wood | Overweight | Initiates | $105.00 |
| Nov 14, 2024 | Jefferies | Michael Sarcone | Hold | Initiates | $95.00 |
| Oct 30, 2024 | Truist Securities | Richard Newitter | Buy | Reiterates | $105.00 |
| Oct 8, 2024 | Piper Sandler | Matt O'Brien | Overweight | Reiterates | $75.00 |
| Sep 16, 2024 | TD Cowen | Joshua Jennings | Buy | Maintains | $99.00 |
| Sep 3, 2024 | Truist Securities | Richard Newitter | Buy | Maintains | $95.00 |
| Aug 22, 2024 | B of A Securities | Craig Bijou | Buy | Maintains | $94.00 |
| Aug 2, 2024 | Truist Securities | Richard Newitter | Buy | Reiterates | $74.00 |
| Aug 2, 2024 | Wells Fargo | Nathan Treybeck | Overweight | Maintains | $69.00 |
| Jul 16, 2024 | Truist Securities | Richard Newitter | Buy | Maintains | $79.00 |
| May 6, 2024 | TD Cowen | Joshua Jennings | Buy | Maintains | $75.00 |
| May 6, 2024 | Piper Sandler | Matt O'Brien | Overweight | Maintains | $75.00 |
| May 2, 2024 | Truist Securities | Richard Newitter | Buy | Maintains | $72.00 |
| Feb 28, 2024 | Truist Securities | Richard Newitter | Buy | Maintains | $58.00 |
Procept BioRobotics Corporation (PRCT) Competitors
The following stocks are similar to PROCEPT based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Procept BioRobotics Corporation (PRCT) Financial Data
Procept BioRobotics Corporation has a market capitalization of $3.17B with a P/E ratio of -32.6x. The company generates $249.12M in trailing twelve-month revenue with a -36.2% profit margin.
Revenue growth is +55.3% quarter-over-quarter, while maintaining an operating margin of -39.7% and return on equity of -27.6%.
Valuation Metrics
Market Cap
$3.17B
Enterprise Value
$2.95B
P/E Ratio
-32.6x
PEG Ratio
-43.1x
Price/Sales
12.7x
Growth & Margins
Revenue Growth (YoY)
+55.3%
Gross Margin
+63.9%
Operating Margin
-39.7%
Net Margin
-36.2%
EPS Growth
+55.3%
Financial Health
Cash/Price Ratio
+10.0%
Current Ratio
8.9x
Debt/Equity
21.0x
ROE
-27.6%
ROA
-13.4%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Procept BioRobotics Corporation (PRCT) Business Model
About Procept BioRobotics Corporation
What They Do
Develops surgical robotics technology for urological health.
Business Model
The company generates revenue by developing and commercializing its AquaBeam Robotic System, which offers a minimally invasive treatment for lower urinary tract symptoms. By providing advanced surgical solutions, Procept BioRobotics caters to the growing demand for innovative medical devices in urology, targeting a specific market segment of older men affected by benign prostatic hyperplasia.
Additional Information
Procept BioRobotics is positioned as a leader in the medical device industry, focusing on autonomous tissue resection to enhance surgical efficiency and safety. As healthcare increasingly prioritizes precision medicine and minimally invasive procedures, the company's technologies are becoming increasingly significant, reflecting broader trends in medical treatment advancements.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
756
CEO
Dr. Reza Zadno Ph.D.
Country
United States
IPO Year
2021
Website
www.procept-biorobotics.comProcept BioRobotics Corporation (PRCT) Latest News & Analysis
Latest News
Quick Summary
Industrial robots, utilized for automated tasks on manufacturing lines, have been in use for decades, indicating their established role in the manufacturing sector.
Why It Matters
Growth in industrial robot usage signals increased automation, potentially boosting productivity and profit margins for manufacturing companies, influencing investment decisions in the sector.
Source: Market Watch
Market Sentiment:
Positive
Quick Summary
PROCEPT BioRobotics (Nasdaq: PRCT) will present at four investor conferences in May and June, highlighting its focus on advancing surgical robotics in urology.
Why It Matters
PROCEPT BioRobotics' management presentations at investor conferences indicate potential growth opportunities and heightened interest, which can influence stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
PROCEPT BioRobotics will hold its Q1 2025 earnings conference call on April 24, 2025, at 8:00 AM ET, featuring key company executives and analysts from various firms.
Why It Matters
The earnings call indicates upcoming financial performance insights, which can influence stock price and investor sentiment regarding PROCEPT BioRobotics.
Source: Seeking Alpha
Market Sentiment:
Neutral
PROCEPT BioRobotics Reports First Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
2 months ago
Quick Summary
PROCEPT BioRobotics (Nasdaq: PRCT) reported unaudited financial results for Q1 2025, focusing on advancements in surgical robotics for urology. Further details on performance were not provided.
Why It Matters
PROCEPT BioRobotics' quarterly financial results could influence stock performance, reflecting its growth potential and operational efficiency in the competitive surgical robotics market.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
PROCEPT BioRobotics (PRCT) reported a quarterly loss of $0.45 per share, better than the expected loss of $0.49, and an improvement from a loss of $0.51 per share a year prior.
Why It Matters
PRCT's smaller-than-expected quarterly loss signals improved financial performance, which may boost investor confidence and impact stock valuations positively.
Source: Zacks Investment Research
Market Sentiment:
Negative
PROCEPT BioRobotics' Aquablation Therapy Spotlighted at 2025 AUA Annual Meeting Along with Expert-Led Workshops
2 months ago
Quick Summary
PROCEPT BioRobotics (Nasdaq: PRCT) will showcase its HYDROS Robotic System and present on BPH treatment outcomes at the AUA Annual Meeting from April 26–29, 2025, in Las Vegas.
Why It Matters
Positive clinical outcomes and innovative technology in BPH treatment can drive demand for PROCEPT's products, potentially boosting revenue and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PRCT Stock
What is Procept BioRobotics Corporation's (PRCT) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, Procept BioRobotics Corporation (PRCT) has a median price target of $77.50. The highest price target is $90.00 and the lowest is $60.00.
Is PRCT stock a good investment in 2026?
According to current analyst ratings, PRCT has 8 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $56.97. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PRCT stock?
Wall Street analysts predict PRCT stock could reach $77.50 in the next 12 months. This represents a 36.0% increase from the current price of $56.97. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Procept BioRobotics Corporation's business model?
The company generates revenue by developing and commercializing its AquaBeam Robotic System, which offers a minimally invasive treatment for lower urinary tract symptoms. By providing advanced surgical solutions, Procept BioRobotics caters to the growing demand for innovative medical devices in urology, targeting a specific market segment of older men affected by benign prostatic hyperplasia.
What is the highest forecasted price for PRCT Procept BioRobotics Corporation?
The highest price target for PRCT is $90.00 from Richard Newitter at Truist Securities, which represents a 58.0% increase from the current price of $56.97.
What is the lowest forecasted price for PRCT Procept BioRobotics Corporation?
The lowest price target for PRCT is $60.00 from at , which represents a 5.3% increase from the current price of $56.97.
What is the overall PRCT consensus from analysts for Procept BioRobotics Corporation?
The overall analyst consensus for PRCT is bullish. Out of 15 Wall Street analysts, 8 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $77.50.
How accurate are PRCT stock price projections?
Stock price projections, including those for Procept BioRobotics Corporation, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 8, 2025 11:48 AM UTC